Impact of Lifestyle and Socioeconomic Position on the Association Between Non-steroidal Anti-inflammatory Drug Use and Major Adverse Cardiovascular Events: A Case-Crossover Study.


Journal

Drug safety
ISSN: 1179-1942
Titre abrégé: Drug Saf
Pays: New Zealand
ID NLM: 9002928

Informations de publication

Date de publication:
06 2023
Historique:
accepted: 20 03 2023
medline: 29 5 2023
pubmed: 3 5 2023
entrez: 2 5 2023
Statut: ppublish

Résumé

It is unknown whether the cardiovascular risks associated with non-steroidal anti-inflammatory drug (NSAID) use differ according to lifestyle and socioeconomic position. We examined the association between NSAID use and major adverse cardiovascular events (MACE) within subgroups defined by lifestyle and socioeconomic position. We conducted a case-crossover study of all adult first-time respondents to the Danish National Health Surveys of 2010, 2013, or 2017, without previous cardiovascular disease, who experienced a MACE from survey completion through 2020. We used a Mantel-Haenszel method to obtain odds ratios (ORs) of the association between NSAID use (ibuprofen, naproxen, or diclofenac) and MACE (myocardial infarction, ischemic stroke, heart failure, or all-cause death). We identified NSAID use and MACE via nationwide Danish health registries. We stratified the analyses by body mass index, smoking status, alcohol consumption, physical activity level, marital status, education, income, and employment. Compared with non-use, the OR of MACE was 1.34 (95% confidence interval: 1.23-1.46) for ibuprofen, 1.48 (1.04-2.43) for naproxen, and 2.18 (1.72-2.78) for diclofenac. When comparing NSAID use with non-use or the individual NSAIDs with each other, we observed no notable heterogeneity in the ORs within subgroups of lifestyle and socioeconomic position for any NSAID. Compared with ibuprofen, diclofenac was associated with increased risk of MACE in several subgroups with high cardiovascular risk, e.g., individuals with overweight (OR 1.52, 1.01-2.39) and smokers (OR 1.54, 0.96-2.46). The relative increase in cardiovascular risk associated with NSAID use was not modified by lifestyle or socioeconomic position.

Identifiants

pubmed: 37131013
doi: 10.1007/s40264-023-01298-0
pii: 10.1007/s40264-023-01298-0
pmc: PMC10219866
doi:

Substances chimiques

Ibuprofen WK2XYI10QM
Diclofenac 144O8QL0L1
Naproxen 57Y76R9ATQ
Anti-Inflammatory Agents, Non-Steroidal 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

533-543

Informations de copyright

© 2023. The Author(s).

Références

Pharmacoepidemiol Drug Saf. 2023 Apr;32(4):455-467
pubmed: 36382802
BMJ. 2005 Mar 12;330(7491):594-6
pubmed: 15761002
BMJ. 2018 Sep 4;362:k3426
pubmed: 30181258
Int J Cardiol. 2013 Oct 15;168(6):5190-5
pubmed: 23998549
Scand J Public Health. 2022 Mar;50(2):180-188
pubmed: 33161874
J Clin Pharmacol. 2019 Jan;59(1):55-73
pubmed: 30204233
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
J Clin Epidemiol. 2016 Jan;69:107-13
pubmed: 26146090
Can J Cardiol. 2021 Nov;37(11):1705-1707
pubmed: 34182020
JAMA. 2003 May 21;289(19):2575-7
pubmed: 12759328
Eur Heart J Cardiovasc Pharmacother. 2021 Nov 3;7(6):496-506
pubmed: 32584988
BMC Med Res Methodol. 2021 Oct 17;21(1):214
pubmed: 34657592
BMJ. 2015 Apr 20;350:h1551
pubmed: 25896935
Scand J Public Health. 2011 Jul;39(7 Suppl):95-8
pubmed: 21775363
J Hum Hypertens. 2000 Feb;14(2):83-90
pubmed: 10723112
Am J Epidemiol. 1991 Jan 15;133(2):144-53
pubmed: 1985444
Clin Epidemiol. 2014 May 12;6:155-68
pubmed: 24872722
Eur J Epidemiol. 2013 Oct;28(10):807-14
pubmed: 24037117
Circulation. 2022 Feb 8;145(6):416-423
pubmed: 35130054
Int J Epidemiol. 2017 Jun 1;46(3):798-798f
pubmed: 27789670
Heart. 2009 Dec;95(24):2014-22
pubmed: 19822574
Clin Epidemiol. 2019 Jul 12;11:563-591
pubmed: 31372058
Eur Heart J. 2022 May 7;43(18):1743-1755
pubmed: 35201347
Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):559-70
pubmed: 23616423
J Clin Epidemiol. 1994 Feb;47(2):183-9
pubmed: 8113827
JAMA. 2003 Feb 5;289(5):579-88
pubmed: 12578491
Int J Epidemiol. 2005 Jun;34(3):680-7
pubmed: 15802377
JAMA. 2010 Jan 20;303(3):267-8
pubmed: 20085955
J Clin Epidemiol. 2002 Jun;55(6):602-7
pubmed: 12063102
Am J Epidemiol. 2021 Oct 1;190(10):2181-2187
pubmed: 33861309
N Engl J Med. 1986 Mar 6;314(10):605-13
pubmed: 3945246
FASEB J. 2008 Feb;22(2):383-90
pubmed: 17884974
Med Care. 2005 Nov;43(11):1130-9
pubmed: 16224307
Ann Rheum Dis. 2016 Mar;75(3):552-9
pubmed: 25732175
J Mol Med (Berl). 2007 Jun;85(6):623-33
pubmed: 17318614
Eur Heart J. 2016 Apr 1;37(13):1015-23
pubmed: 26984863
Int J Epidemiol. 2001 Oct;30(5):1119-26
pubmed: 11689532
Heart Rhythm. 2011 Aug;8(8):1160-6
pubmed: 21419237
J Clin Epidemiol. 2010 Apr;63(4):422-7
pubmed: 19880282
Clin Epidemiol. 2015 Nov 17;7:449-90
pubmed: 26604824
Lancet. 2013 Aug 31;382(9894):769-79
pubmed: 23726390
Eur J Epidemiol. 2014 Aug;29(8):541-9
pubmed: 24965263
Scand J Public Health. 2011 Jul;39(7 Suppl):103-5
pubmed: 21775365
Arch Intern Med. 2005 Mar 14;165(5):490-6
pubmed: 15710786
Int Arch Occup Environ Health. 2015 Aug;88(6):707-16
pubmed: 25385250
Arch Intern Med. 2006 Dec 11-25;166(22):2437-45
pubmed: 17159008
BMJ. 1998 Apr 4;316(7137):1043-7
pubmed: 9552903
Arch Intern Med. 2012 Dec 10;172(22):1731-7
pubmed: 23401888
Eur Heart J. 2017 Aug 21;38(32):2459-2472
pubmed: 28444290
J Epidemiol. 2012;22(2):123-9
pubmed: 22245707
JAMA. 1996 Jul 17;276(3):205-10
pubmed: 8667564
Lancet. 2004 Sep 11-17;364(9438):937-52
pubmed: 15364185
BMJ Open. 2015 Mar 17;5(3):e006408
pubmed: 25783421
BMJ Open. 2016 Nov 18;6(11):e012832
pubmed: 27864249
Addiction. 2000 Oct;95(10):1505-23
pubmed: 11070527
Lancet. 2009 Mar 28;373(9669):1083-96
pubmed: 19299006
Heart. 2018 Dec;104(23):1937-1948
pubmed: 29921571
J Intern Med. 2014 Jun;275(6):581-9
pubmed: 24635348
BMJ. 2011 Jan 11;342:c7086
pubmed: 21224324
Annu Rev Med. 2010;61:17-33
pubmed: 20059330
JAMA Cardiol. 2018 Apr 1;3(4):280-287
pubmed: 29490333

Auteurs

Kasper Bonnesen (K)

Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark. bonnesen@clin.au.dk.

Lars Pedersen (L)

Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark.

Vera Ehrenstein (V)

Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark.

Marie Stjerne Grønkjær (MS)

Center for Clinical Research and Prevention, Copenhagen University Hospital-Bispebjerg and Frederiksberg, Copenhagen, Denmark.

Henrik Toft Sørensen (HT)

Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark.

Jesper Hallas (J)

Clinical Pharmacology, Pharmacy and Environmental Medicine, Institute of Public Health, University of Southern Denmark, Odense, Denmark.

Timothy Lee Lash (TL)

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA.

Morten Schmidt (M)

Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Olof Palmes Allé 43-45, 8200, Aarhus N, Denmark.
Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH